English
Français
Deutsch
Italiano
Русский
Español
हिन्दी
简体中文
한국어
日本語
Conference Call Participants
Samuel Slutsky – LifeSci Capital, LLC, Research Division
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Samantha Lynn Semenkow – Citigroup Inc. Exchange Research
David Risinger – Leerink Partners LLC, Research Division
Yaron Werber – TD Cowen, Research Division
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Leland Gershell – Oppenheimer & Co. Inc., Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Sean Kim – JPMorgan Chase & Co, Research Division
Georgia Calhoun
Jason Gerberry – BofA Securities, Research Division
Charles Ndiaye – Stifel, Nicolaus & Company, Incorporated, Research Division
Nathanael Charoensook – Leerink Partners LLC, Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Immunovant Graves’ Disease Data Update Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the call over to your first speaker today, Stephanie Lee. Please go ahead.
Stephanie Lee Griffin
Chief Operating Officer of Roivant Platforms
Good afternoon, and thanks for joining today’s call to review the Immunovant Graves’ disease data. I’m Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant.
For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We’ll also be providing the current slide numbers as we present to help you follow along.
I would like to remind you that we will be making certain forward-looking statements during today’s presentation. We strongly encourage you to review the information that we have filed with the SEC for more
Read the full article here
